Clinical Trial Update: A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ABT-494 (Upadacitinib) in adults with moderate to severe atopic dermatitis has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ABT-494 (Upadacitinib) (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2020-07-16